<?xml version="1.0" encoding="UTF-8"?>
<project>
  <language>en</language>
  <availableLanguages readOnly="true">en</availableLanguages>
  <rcn>260119</rcn>
  <id>101144681</id>
  <acronym>MYCureX</acronym>
  <teaser>Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite recent advances, cancer therapies remain ineffective and/or highly toxic. Our approach is targeting MYC, a function essential to cancer...</teaser>
  <objective><![CDATA[Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with very few and often ineffective therapeutic options. Despite recent advances, cancer therapies remain ineffective and/or highly toxic. Our approach is targeting MYC, a function essential to cancer cells that allows them to survive and develop resistance to therapy. In contrast to standard drugs, inhibiting MYC selectively blocks tumor progression without causing important side effects. MYC has been considered undruggable for a long time, and no clinical MYC inhibitor is yet marketed. Peptomycs first-in-class drug, OMO-103, is a cell-penetrating mini-protein that derives from Omomyc, the best MYC inhibitor known to date. OMO-103 recently completed a Phase 1 clinical trial that confirmed its safety and clinical activity in all-comers solid tumor patients, causing a 49% tumor shrinkage in a PDAC patient and stabilizing the disease of 8 out of 12 evaluable patients. Moreover, using AI we identified a predictive and a pharmacodynamic circulating biomarker signatures, and generated companion diagnostic for stratification and real-time response monitoring tests for OMO-103. OMO-103 and its companion diagnostic tests offer a promising therapeutic option for a disease in great need and could apply to treat many other cancer indications. The next steps and goals of this MYCureX project consist of conducting a Phase 1b trial in 1st-line PDAC patients, combining OMO-103 with the standard of care, to evaluate its safety and clinical activity; refining the companion diagnostic prototypes and app; securing the scale-up of the innovation by developing a commercial-scale compatible manufacturing process; and expand the applications of OMO-103 and Peptomyc's drug pipeline. By completing MYCureX, Peptomyc will consolidate the therapeutic potential of MYC inhibition in cancer patients, improving their survival and quality of life while establishing itself as a European leader biotech in MYC targeting.]]></objective>
  <title>FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY</title>
  <keywords>MYC, Undruggable target, Cell-penetrating mini-protein drug, First-in-class, First-in-modality, Companion diagnostic, Machine learning-enabled biomarkers discovery, Omics</keywords>
  <totalCost>3563578.25</totalCost>
  <ecMaxContribution>2494504</ecMaxContribution>
  <startDate>2023-07-01</startDate>
  <endDate>2025-12-31</endDate>
  <ecSignatureDate>2024-02-08</ecSignatureDate>
  <duration>30</duration>
  <status>SIGNED</status>
  <identifiers>
    <grantDoi>10.3030/101144681</grantDoi>
  </identifiers>
  <validation>
    <euroSciVoc>false</euroSciVoc>
  </validation>
  <sourceUpdateDate>2024-12-31 09:30:22</sourceUpdateDate>
  <contentCreationDate readOnly="true">2024-02-13 18:46:08</contentCreationDate>
  <contentUpdateDate>2025-09-01 23:33:11</contentUpdateDate>
  <lastUpdateDate readOnly="true">2025-09-19 14:48:42</lastUpdateDate>
  <relations>
    <associations>
      <article source="editorial" type="relatedArticle">
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <rcn>449795</rcn>
        <id>449795-inhibition-of-myc-in-pancreatic-cancer</id>
        <title>Inhibition of MYC in pancreatic cancer</title>
        <contentUpdateDate>2024-06-06 16:54:00</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/projectDescription</code>
              <title>Project description</title>
              <description>Article: description of linked project written by editorial team</description>
              <displayCode readOnly="true">/Project description</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/editorial</code>
              <title>CORDIS Editorial</title>
              <description>Written by CORDIS</description>
              <displayCode readOnly="true">/CORDIS Editorial</displayCode>
            </category>
          </categories>
        </relations>
      </article>
      <call source="corda" type="relatedMasterCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <call source="corda" type="relatedSubCall">
        <rcn>55873</rcn>
        <title>HORIZON-EIC-2023-ACCELERATOR-01</title>
        <identifier>HORIZON-EIC-2023-ACCELERATOR-01</identifier>
      </call>
      <organization source="corda" order="1" ecContribution="2494504" terminated="false" sme="true" netEcContribution="2494504" totalCost="3563578.25" type="coordinator">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>2384571</rcn>
        <id>934454545</id>
        <vatNumber>ESB66430653</vatNumber>
        <legalName>PEPTOMYC SL</legalName>
        <shortName>PEPTOMYC SL</shortName>
        <address>
          <street>CENTER CELLEX, CALLE NATZARET 115-117</street>
          <city>BARCELONA</city>
          <postalCode>08035</postalCode>
          <country>ES</country>
          <geolocation>41.370449300000004,2.1500219563810696</geolocation>
        </address>
        <relations>
          <categories>
            <category classification="organizationActivityType" type="relatedOrganizationActivityType">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/PRC</code>
              <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
              <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
            </category>
          </categories>
          <regions>
            <region type="relatedNutsCode">
              <name>Spain</name>
              <rcn>242387496</rcn>
              <nutsCode>ES</nutsCode>
              <euCode>ES</euCode>
              <isoCode>ES</isoCode>
            </region>
            <region type="relatedRegion">
              <name>Spain</name>
              <rcn>242387496</rcn>
              <nutsCode>ES</nutsCode>
              <euCode>ES</euCode>
              <isoCode>ES</isoCode>
            </region>
          </regions>
        </relations>
      </organization>
      <programme source="corda" uniqueProgrammePart="true" type="relatedLegalBasis">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>705792</rcn>
        <id>HORIZON.3.1</id>
        <code>HORIZON.3.1</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <pga>HORIZON.3.1</pga>
        <title>The European Innovation Council (EIC)</title>
        <parent>
          <programme>
            <rcn>705791</rcn>
            <code>HORIZON.3</code>
            <parent>
              <programme>
                <rcn>705725</rcn>
                <code>HORIZON</code>
              </programme>
            </parent>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/legalbasis</code>
              <title>Legal Basis</title>
              <description>Programme: Legal basis for research funding</description>
              <displayCode readOnly="true">/Legal Basis</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <programme source="corda" type="relatedTopic">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>707276</rcn>
        <id>HORIZON_HORIZON-EIC-2023-ACCELERATOROPEN-01</id>
        <code>HORIZON-EIC-2023-ACCELERATOROPEN-01</code>
        <frameworkProgramme>HORIZON</frameworkProgramme>
        <title>EIC Accelerator Open 2023</title>
        <parent>
          <programme>
            <rcn>20300</rcn>
            <code>HORIZON-Topics</code>
          </programme>
        </parent>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/topic</code>
              <title>Topic</title>
              <description>Programme: Part of the Commission work programme implementing legal basis</description>
              <displayCode readOnly="true">/Topic</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
        </relations>
      </programme>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1124929</rcn>
        <id>101144681_PSHORIZON</id>
        <title>Periodic Reporting for period 2 - MYCureX (FIRST-IN-CLASS MYC INHIBITOR: THE MAKING OF A BREAKTHROUGH CANCER THERAPY)</title>
        <teaser>Cancers are a leading cause of mortality, accounting for nearly 10 million (M) annual deaths worldwide. Personalized medicine and immunotherapy have improved the prognosis for several patients, yet their applicability remains limited, often targeting redundant cell functions...</teaser>
        <description>periodic</description>
        <sourceUpdateDate>2025-06-11 22:15:29</sourceUpdateDate>
        <contentUpdateDate>2025-06-11 22:15:29</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/pubsum</code>
              <title>Report Summary</title>
              <description>Result: Publishable summary (FP7 SESAM) and Summary for publication (H2020 SyGMa)</description>
              <displayCode readOnly="true">/Report Summary</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
          <associations>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-3.png</uri>
              <alternativeText>Peptomyc published the results of the OMO-103 FIH trial in Nature Medicine</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">366592</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-4.png</uri>
              <alternativeText>Peptomyc presented the company’s project at Bio-Europe Spring 2024</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">526336</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/myc-kras.png</uri>
              <alternativeText>Publication of a review article on the cooperation between MYC and RAS in cancer</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">169984</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/osteosarcoma.png</uri>
              <alternativeText>Peptomyc announces the beginning of an investigator-led Phase II trial in osteosarcoma</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">45056</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-5.png</uri>
              <alternativeText>Peptomyc was awarded as the most innovative company of the year by El Periódico</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">1423360</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/myc-cancer.png</uri>
              <alternativeText>Publication of a review article about the journey of targeting MYC in Nature Reviews Drug Discovery</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">167936</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/patent.png</uri>
              <alternativeText>Peptomyc announces the expansion of its patent portfolio</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">62464</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/indapproval.png</uri>
              <alternativeText>Peptomyc announces IND approval to conduct a WoO trial in the U.S. in PDAC patients.</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">119808</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-2.png</uri>
              <alternativeText>Peptomyc announces first patient dosed in Phase Ib trial</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">153600</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/premis.png</uri>
              <alternativeText>Laura Soucek, CEO of Peptomyc, receiving the Premi Ciutat de Barcelona</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">251904</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/sandiego.png</uri>
              <alternativeText>Peptomyc representing its research and innovation at BIO International Convention in San Diego</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">227328</size>
            </webItem>
            <webItem source="corda" type="relatedResultAttachment">
              <language>en</language>
              <availableLanguages readOnly="true">en,any</availableLanguages>
              <uri>/docs/results/horizon/101144/101144681_PS/figure-1.png</uri>
              <alternativeText>Peptomyc announces the approval of its phase 1b trial</alternativeText>
              <mimetype readOnly="true">image/png</mimetype>
              <size readOnly="true">151552</size>
            </webItem>
          </associations>
        </relations>
      </result>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1237574</rcn>
        <id>101144681_CFA069B7D8A12C2D44DD37B792D3BC4C_IPRHORIZON</id>
        <title>Compound for the treatment of autoimmune diseases</title>
        <details>
          <iprAwarded/>
          <iprDate>2024-03-11</iprDate>
          <iprNumber>EP24382257.4</iprNumber>
          <iprPrefix>EP24382257.4</iprPrefix>
        </details>
        <sourceUpdateDate>2025-01-10 11:51:31</sourceUpdateDate>
        <contentUpdateDate>2025-01-10 11:51:31</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/ipr</code>
              <title>Intellectual Property Rights</title>
              <description>Result: Intellectual property rights linked to the results of EU funded research (FP7 onwards)</description>
              <displayCode readOnly="true">/Intellectual Property Rights</displayCode>
            </category>
            <category classification="iprType" type="isRegisteredAs">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/OTHER</code>
              <title>Other</title>
              <displayCode readOnly="true">/Other</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
          <associations>
            <organization source="corda" type="isRegisteredBy">
              <availableLanguages readOnly="true">en</availableLanguages>
              <rcn>2384571</rcn>
              <id>934454545</id>
              <vatNumber>ESB66430653</vatNumber>
              <legalName>PEPTOMYC SL</legalName>
              <shortName>PEPTOMYC SL</shortName>
              <address>
                <street>CENTER CELLEX, CALLE NATZARET 115-117</street>
                <city>BARCELONA</city>
                <postalCode>08035</postalCode>
                <country>ES</country>
                <geolocation>41.370449300000004,2.1500219563810696</geolocation>
              </address>
              <relations>
                <categories>
                  <category classification="organizationActivityType" type="relatedOrganizationActivityType">
                    <language>en</language>
                    <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
                    <code>/PRC</code>
                    <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
                    <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
                  </category>
                </categories>
                <regions>
                  <region type="relatedNutsCode">
                    <name>Spain</name>
                    <rcn>242387496</rcn>
                    <nutsCode>ES</nutsCode>
                    <euCode>ES</euCode>
                    <isoCode>ES</isoCode>
                  </region>
                  <region type="relatedRegion">
                    <name>Spain</name>
                    <rcn>242387496</rcn>
                    <nutsCode>ES</nutsCode>
                    <euCode>ES</euCode>
                    <isoCode>ES</isoCode>
                  </region>
                </regions>
              </relations>
            </organization>
          </associations>
        </relations>
      </result>
      <result source="corda" type="relatedResult">
        <availableLanguages readOnly="true">en</availableLanguages>
        <rcn>1318343</rcn>
        <id>101144681_E0540AFB3C76218E76013F1BFA33FAB1_IPRHORIZON</id>
        <title>Compound for the treatment of autoimmune diseases</title>
        <details>
          <iprAwarded/>
          <iprDate>2024-03-11</iprDate>
          <iprNumber>EP24382257.4</iprNumber>
          <iprPrefix>EP24382257.4</iprPrefix>
        </details>
        <sourceUpdateDate>2025-06-09 13:13:44</sourceUpdateDate>
        <contentUpdateDate>2025-06-09 13:13:44</contentUpdateDate>
        <relations>
          <categories>
            <category classification="collection" type="belongsTo">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/ipr</code>
              <title>Intellectual Property Rights</title>
              <description>Result: Intellectual property rights linked to the results of EU funded research (FP7 onwards)</description>
              <displayCode readOnly="true">/Intellectual Property Rights</displayCode>
            </category>
            <category classification="iprType" type="isRegisteredAs">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/OTHER</code>
              <title>Other</title>
              <displayCode readOnly="true">/Other</displayCode>
            </category>
            <category classification="source" type="isProvidedBy">
              <language>en</language>
              <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
              <code>/corda</code>
              <title>CORDA</title>
              <description>RTD research data warehouse</description>
              <displayCode readOnly="true">/CORDA</displayCode>
            </category>
          </categories>
          <associations>
            <organization source="corda" type="isRegisteredBy">
              <availableLanguages readOnly="true">en</availableLanguages>
              <rcn>2384571</rcn>
              <id>934454545</id>
              <vatNumber>ESB66430653</vatNumber>
              <legalName>PEPTOMYC SL</legalName>
              <shortName>PEPTOMYC SL</shortName>
              <address>
                <street>CENTER CELLEX, CALLE NATZARET 115-117</street>
                <city>BARCELONA</city>
                <postalCode>08035</postalCode>
                <country>ES</country>
                <geolocation>41.370449300000004,2.1500219563810696</geolocation>
              </address>
              <relations>
                <categories>
                  <category classification="organizationActivityType" type="relatedOrganizationActivityType">
                    <language>en</language>
                    <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
                    <code>/PRC</code>
                    <title>Private for-profit entities (excluding Higher or Secondary Education Establishments)</title>
                    <displayCode readOnly="true">/Private for-profit entities (excluding Higher or Secondary Education Establishments)</displayCode>
                  </category>
                </categories>
                <regions>
                  <region type="relatedNutsCode">
                    <name>Spain</name>
                    <rcn>242387496</rcn>
                    <nutsCode>ES</nutsCode>
                    <euCode>ES</euCode>
                    <isoCode>ES</isoCode>
                  </region>
                  <region type="relatedRegion">
                    <name>Spain</name>
                    <rcn>242387496</rcn>
                    <nutsCode>ES</nutsCode>
                    <euCode>ES</euCode>
                    <isoCode>ES</isoCode>
                  </region>
                </regions>
              </relations>
            </organization>
          </associations>
        </relations>
      </result>
    </associations>
    <categories>
      <category classification="collection" type="belongsTo">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/project</code>
        <title>Project</title>
        <description>Project factsheets</description>
        <displayCode readOnly="true">/Project</displayCode>
      </category>
      <category classification="euroSciVoc" type="isInFieldOfScience">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/21/39/225</code>
        <title>oncology</title>
        <displayCode readOnly="true">/medical and health sciences/clinical medicine/oncology</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/digitalAgenda</code>
        <title>Digital agenda</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development of digital technologies and the digitisation of the economy and society (known as ‘Digital transition’).</description>
        <displayCode readOnly="true">/Digital agenda</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/cleanAir</code>
        <title>Clean air</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to the clean air policy (National Emission Ceiling Directive) aiming to improve ambient air quality and tackle air pollution, to protect the environment and human health.</description>
        <displayCode readOnly="true">/Clean air</displayCode>
      </category>
      <category weight="40" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/ai</code>
        <title>Artificial intelligence</title>
        <description>This tracker monitors Horizon Europe’s financial contribution to the development and deployment of AI-based technologies and solutions. Projects that develop AI-tools as part of their research method are included</description>
        <displayCode readOnly="true">/Artificial intelligence</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/climate</code>
        <title>Climate action</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to both mitigating climate change (e.g., contributions to the reduction of greenhouse gas emissions) and adapting to climate change by building resilience (e.g., regarding floods, droughts, spatial planning and better governance, adaptation to changing climate in value chains, etc.).</description>
        <displayCode readOnly="true">/Climate action</displayCode>
      </category>
      <category weight="0" classification="policyPriorities" type="marker">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/biodiversity</code>
        <title>Biodiversity</title>
        <description>This tracker monitors the Horizon Europe’s financial contribution to Europe’s biodiversity’s path to recovery including species protection, ecosystem conservation, and habitat rehabilitation, all essential for resilience in climate adaptation and addressing ecosystem services but also environmental crime and the health-environment connection.</description>
        <displayCode readOnly="true">/Biodiversity</displayCode>
      </category>
      <category classification="projectFundingSchemeCategory" type="relatedProjectFundingSchemeCategory">
        <language>en</language>
        <availableLanguages readOnly="true">en</availableLanguages>
        <code>/HORIZON-EIC-ACC-BF</code>
        <title>HORIZON EIC Accelerator Blended Finance</title>
        <description>HORIZON EIC Accelerator Blended Finance</description>
        <displayCode readOnly="true">/HORIZON EIC Accelerator Blended Finance</displayCode>
      </category>
      <category classification="source" type="isProvidedBy">
        <language>en</language>
        <availableLanguages readOnly="true">de,en,es,fr,it,pl</availableLanguages>
        <code>/corda</code>
        <title>CORDA</title>
        <description>RTD research data warehouse</description>
        <displayCode readOnly="true">/CORDA</displayCode>
      </category>
    </categories>
  </relations>
</project>
